Close

IMGN Financial Facts

Clinical materials reimbursement: 46K
Research and development support: 1.35M
See Full Income Statement

Deferred revenue, net of current portion: 19.16M
Cash and cash equivalents: 196M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 4/25/24 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +73.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +51.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/1/14 Q414 -$0.83-$0.32 -$0.51$5.74M$9.72M N/A Details
11/3/17 Q317 -$0.61-$0.19 -$0.42$8.5M$33.62M = Details
7/31/15 Q415 -$0.71-$0.35 -$0.36$12.61M$15.42M N/A Details
2/25/22 Q421 -$0.17N/A N/A $28M$85.8M = Details
4/25/14 Q314 -$0.44-$0.27 -$0.17$6.9M$13.28M = Details
2/12/24 Q423 N/A$0.13 N/A N/A$129.48M N/A N/A N/A
10/28/16 Q117 -$0.51-$0.38 -$0.13$7.66M$21.12M = Details
2/9/24 Q423 N/A$0.13 N/A N/A$129.48M N/A N/A N/A